A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Deucrictibant (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms RAPIDe-3
- Sponsors Pharvaris
Most Recent Events
- 13 Jan 2025 According to Pharvaris media release, enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026
- 16 Oct 2024 According to Pharvaris media release, RAPIDe-3 phase 3 trial design will be presented as an oral presentation by Prof. Michihiro Hide, M.D., Ph.D. on Sunday, Oct. 20, 13:30-14:45 JST at Japanese Society of Allergology (JSA), Kyoto, Japan, being held October 18-20, 2024.
- 03 Oct 2024 According to Pharvaris media release, data from this study has been accepted and will be presented at the 2024 Global Angioedema Forum- HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024.